Systolic Heart failure treatment with

the If inhibitor ivabradine Trial

Efficacy and safety of ivabradine in chronic

heart failure across the age spectrum:

insights from the SHIFT study

www.shift-study.comTavazzi L, et al. Eur J Heart Fail. 2013;15(11):1296-1303

Age does not limit the efficacy of ivabradine in patients with CHF and LVSD

Tavazzi L, et al. Eur J Heart Fail. 2013;15(11):1296-1303 www.shift-study.com

In very elderly patients (≥75 years; n=722), ivabradine reduces

CV death (16% vs 22%; P=0.048) and HF death (4% vs 8% P=0.019)

Age does not limit the efficacy of ivabradine in patients with CHF and LVSD

Incidence of CV death or hospitalization for worsening HF in patients

in the lowest and highest quartiles of age

www.shift-study.comTavazzi L, et al. Eur J Heart Fail. 2013;15(11):1296-1303